b-AP15 inhibits tumor growth and prolongs survival in xenograft mouse model. MM.1S cells (5 × 106) were subcutaneously inoculated into mouse hind flank region. On days 21 to 23, when the tumors reached 150 to 200 mm3, mice were randomized to control or b-AP15 treatment groups (7 mice in each group) and treated with vehicle control or b-AP15 (4 mg/kg) for 14 consecutive days. (A) Tumor volume was measured every other day. Data shown are mean ± SD (n = 7; P < .001). (B) Mice were euthanized when tumor volume reached 2000 mm3, and survival is shown in a Kaplan-Meier plot (P < .05). (C) Tumor sections from control and b-AP15–treated mice were immunostained with anti–caspase 3, Ki67, VEGF, VEGFR2, LYVE1, or CD31 antibodies. Scale bar = 10 μM. (D) Mouse body weight was measured every other day. Data shown are mean ± SD. (E) Hemoglobin, creatinine, and bilirubin from mouse serum were measured at the end of treatment. Data shown are mean ± SD.
